Article Text

Download PDFPDF

719 Phase 1 clinical trial design of ZM008, a first-in-class anti LLT1 antibody is a promising therapy for multiple solid cancers
  1. Maloy Ghosh,
  2. Anurag Tiwari,
  3. Ashvini Kumar Dubey,
  4. Sanghamitra Bhattacharjee,
  5. Yogendra Manjunath,
  6. Shalini Kashipathi,
  7. Subith Krishna,
  8. Tirtha Mandal,
  9. Soorya Gnanasegaran and
  10. Ignacio Garcia-Ribas
  1. Zumutor Biologics Pvt Ltd, Bangalore, India
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Lectin-like transcript 1 (LLT1) interaction with CD161 on NK cells facilitates tumor immune escape.1–3 The novel anti LLT1 antibody, ZM008 disrupts LLT1-CD161 interaction to activate NK cells, improve immune cell infiltration and enhance tumor cell cytotoxicity.4–6 Present work describes biomarker strategy and unique clinical protocol to conduct phase 1 studies with ZM008.

Methods The Cancer Genome Atlas (TCGA) data was used to understand expression of LLT1 in 33 cancers. Correlation analysis was performed to compare LLT1 expression with immune gene signatures. Multiple pharmacodynamics (PD) parameters were used to determine minimum anticipated biological effect level (MABEL), biological effective dose (BED) including, in vitro assays for cytokine release, PBMC receptor occupancy, proliferation assays, in vivo and ex vivo efficacy studies, safety and toxicity studies.

Results TCGA data analysis revealed high expression of LLT1 in multiple cancers like, NSCLC, TNBC, head and neck, prostate and urothelial cancers. In addition, high LLT1 expression is negatively correlated with proinflammatory signals (IL-2, IL-6, EOMES, and LAMP1), and positively correlated with high Treg, CD33+ MDSC, high PD1, LAG3, TIM3, TIGIT, ICOS, high TMB and MSI scores. ZM008 phase I clinical trial will primarily determine single agent safety and tolerability followed by unique BED based dosing strategy to initiate combinatorial arm with Pembrolizumab. Solid tumor patients with advanced metastatic disease with no available therapeutic options will be recruited. Accelerated single patient cohorts and 3+3 study design will evaluate patient safety, tolerability and benefits with ZM008 mediated immune activation following RECIST v1.1. Pembrolizumab combination arm will initiate only after thorough safety evaluation of ZM008 at BED dosing to ensure manageable adverse events with combination treatment (figure 1). Multicohort dose-expansion trial is designed with ZM008 single agent and in combination with Pembrolizumab; RP2D will be determined.

Conclusions The biomarker analysis revealed clear association of high LLT1 expression with immune nonresponsive gene signatures. Retrospective analysis of patient samples from phase 1 study will be explored to identify relevant PD markers for future patient recruitment. ZM008 activates immune cells, hence the clinical protocol was designed with ‘safety first’ approach with MABEL dosing and extensive patient monitoring. In addition, to avoid adverse reactions with Pembrolizumab combination arm we have designed a staggered parallel approach with detailed safety data discussion with the agency at the BED dosing. This unique design allows maximum patient safety while evaluation of novel standalone I/O therapy or combination therapies.


  1. Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, Lanier LL. Cutting edge: Lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 2005;175(12):7796–7799. PMID: 16339513. DOI: 10.4049/jimmunol.175.12.7796

  2. Boles KS, Barten R, Kumaresan PR, Trowsdale J, Mathew PA. Cloning of a new lectin-like receptor expressed on human NK cells. Immunogenetics 1999;50(1–2):1–7. PMID: 10541800. DOI: 10.1007/s002510050679

  3. Mathew PA, Chuang SS, Vaidya SV, Kumaresan PR, Boles KS, Pham HT. The LLT1 receptor induces IFN-gamma production by human natural killer cells. Mol Immunol 2004;40(16):1157–1163. PMID: 15104121. DOI: 10.1016/j.molimm.2003.11.024

  4. Mathew SO, Chaudhary P, Powers SB, Vishwanatha JK, Mathew PA. Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (cd161) interaction. Oncotarget 2016;7(42):68650–68661. PMID: 27626681. DOI: 10.18632/oncotarget.11896

  5. Braud VM, Meghraoui-Kheddar A, Elaldi R, Petti L, Germain C, Anjuère F. LLT1-CD161 Interaction in Cancer: Promises and Challenges. Front. Immunol. 2022;13:847576. doi: 10.3389/fimmu.2022.847576

  6. Gosh M, Rodrigues KI, Maity S, Bhattacharjee S, Manjunath Y, Chakrabarty SP, Dubey AK, Tiwari A, Murugesan S, Halan V. Novel monoclonal antibody therapeutics for metastatic castration resistant prostate cancer. J. Clin. Oncol. 2019;37:e14222.

Abstract 719 Figure 1

Phase 1 trial design of ZM008, as single agent followed by combination with pembrolizumab in patients with advanced solid tumors. Stage 1A describes single patient cohorts accelerated titration design, followed by 3+3 standard design. Accelerated titration will be switched to 3+3 design, when at least 1 or more patient reveals TEAE of Grade ≥2 (including DLT) during the DLT observation period or when 1.0 mg/kg ZM008 dose is reached (whatever happens first). Once ZM008 monotherapy MTD or BED dose (calculated based on safety, efficacy, PK, and pharmacodynamics) is attained, a Phase 1 dose escalation of ZM008 in combination with Pembrolizumab will be initiated after approval of substantial amendment by the regulatory authorities as described in staggered parallel design (Stage 1B). Pembrolizumab will be infused at a fixed dose of 200mg every three weeks. If no stopping rule is met, it will be possible to continue the escalation of ZM008 as monotherapy above the target BED and in parallel with pembrolizumab combination dose escalation. *ZM008 dose will be defined on the basis of monotherapy information up to MTD/BED. Dose selection in combination will be subjected to reviewed by FDA/IRB. Abbreviations: BED= biological effective dose; DL=dose level; DLT=dose limiting toxicity; MTD=maximum tolerated dose; TBD=to be discussed; TEAE=treatment-emergent adverse event

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.